Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Molecules ; 26(3)2021 Jan 28.
Article in English | MEDLINE | ID: mdl-33525350

ABSTRACT

Plant hormones are small regulatory molecules that exert pharmacological actions in mammalian cells such as anti-oxidative and pro-metabolic effects. Kinetin belongs to the group of plant hormones cytokinin and has been associated with modulatory functions in mammalian cells. The mammalian adenosine receptor (A2a-R) is known to modulate multiple physiological responses in animal cells. Here, we describe that kinetin binds to the adenosine receptor (A2a-R) through the Asn253 residue in an adenosine dependent manner. To harness the beneficial effects of kinetin for future human use, we assess its acute toxicity by analyzing different biochemical and histological markers in rats. Kinetin at a dose below 1 mg/kg had no adverse effects on the serum level of glucose or on the activity of serum alanine transaminase (ALT) or aspartate aminotransferase (AST) enzymes in the kinetin treated rats. Whereas, creatinine levels increased after a kinetin treatment at a dose of 0.5 mg/kg. Furthermore, 5 mg/kg treated kinetin rats showed normal renal corpuscles, but a mild degeneration was observed in the renal glomeruli and renal tubules, as well as few degenerated hepatocytes were also observed in the liver. Kinetin doses below 5 mg/kg did not show any localized toxicity in the liver and kidney tissues. In addition to unraveling the binding interaction between kinetin and A2a-R, our findings suggest safe dose limits for the future use of kinetin as a therapeutic and modulatory agent against various pathophysiological conditions.


Subject(s)
Kinetin/pharmacology , Kinetin/toxicity , Small Molecule Libraries/pharmacology , Small Molecule Libraries/toxicity , Animals , Antioxidants/physiology , Antioxidants/toxicity , Biomarkers/metabolism , Creatinine/metabolism , Cytokinins/metabolism , Glucose/metabolism , Hepatocytes/drug effects , Hepatocytes/metabolism , Humans , Kidney Glomerulus/drug effects , Kidney Glomerulus/metabolism , Kidney Tubules/drug effects , Kidney Tubules/metabolism , Liver/drug effects , Liver/metabolism , Male , Oxidation-Reduction/drug effects , Oxidative Stress/drug effects , Plant Growth Regulators/pharmacology , Plant Growth Regulators/toxicity , Rats , Receptors, Purinergic P1/metabolism
2.
J Cell Biochem ; 102(6): 1405-19, 2007 Dec 15.
Article in English | MEDLINE | ID: mdl-17975794

ABSTRACT

Inhibition of cyclin-dependent kinases (CDKs) is a novel strategy in the therapy of human malignancies. The pharmacological CDK inhibitors representing a few distinct classes of compounds exert different target specificity. Considering the fact that dividing and quiescent cells differ in their CDK activity and in the pattern of their expression, one might expect that anti-proliferative efficiency of the pharmacological CDK inhibitors would depend on the mitotic index of treated cells. The present article shows that olomoucine (OLO), a weak CDK2 inhibitor has new, unexpected activity. At concentrations up to 100 microM OLO did not inhibit proliferation of normal human cells, but arrested growth of human HL-60 leukemia cells. The anti-proliferative effect of OLO was clearly weaker than that of roscovitine (ROSC). Surprisingly, OLO at low doses strongly up-regulated a cellular protein with approximately 65 kDa in normal, but not in immortalized and cancer cells. By mass spectrometric analysis CLIMP-63, a cytoskeleton-linking membrane protein was identified as the major component of the up-regulated protein band. These results were subsequently confirmed by immunoblotting. Further experiments revealed that OLO, but not ROSC, strongly up-regulates CLIMP-63 in a dose- and time-dependent manner solely in senescent cells.


Subject(s)
Cyclin-Dependent Kinases/antagonists & inhibitors , Enzyme Inhibitors/pharmacology , Kinetin/pharmacology , Membrane Proteins/metabolism , Up-Regulation , Animals , Breast Neoplasms/pathology , Cell Line, Transformed , Cell Line, Tumor , Cell Survival/drug effects , DNA/analysis , Dose-Response Relationship, Drug , Embryo, Mammalian , Enzyme Inhibitors/toxicity , HL-60 Cells , Humans , Kinetin/toxicity , Lung/cytology , Mice , Purines/pharmacology , Roscovitine , Skin/cytology , Time Factors , Up-Regulation/drug effects
3.
J Inorg Biochem ; 99(11): 2127-38, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16143400

ABSTRACT

A series of platinum(II) complexes with 2,9-disubstituted-6-benzylaminopurines has been prepared. The complexes have the following composition: cis-[Pt(Boh)(2)Cl(2)] (1), cis-[Pt(Oc)(2)Cl(2)] (2), cis-[Pt(Ros)(2)Cl(2)] (3), cis-[Pt(i-PrOc)(2)Cl(2)] (4), cis-[Pt(BohH(+))(2)Cl(2)]Cl(2) (5), cis-[Pt(OcH(+))(2)Cl(2)]Cl(2) (6), cis-[Pt(RosH(+))(2)Cl(2)]Cl(2) (7) and cis-[Pt(i-PrOcH(+))(2)Cl(2)]Cl(2) (8), where Boh=2-(3-hydroxypropylamino)-6-benzylamino-9-isopropylpurine, Oc=2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine, Ros=2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine and i-PrOc=2-(2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine. The complexes have been characterized by elemental analyses, conductivity measurements and their infrared, ES+mass (electrospray mass spectra in the positive ion mode) and NMR ((1)H, (13)C, (15)N and (195)Pt) spectra. The results obtained from the physical studies, particularly from multinuclear NMR spectroscopy, show that in all the investigated complexes (1-8), two molecules of purine derivative are coordinated to platinum via the N(7) atom of the imidazole ring in a cis-configuration. The prepared compounds have been screened for their in vitro cytotoxicity against G-361 (human malignant melanoma), HOS (human osteogenic sarcoma), K-562 (human chronic myelogenous leukemia) and MCF-7 (human breast adenocarcinoma) cell lines. All complexes are significantly more active than the initial 2,9-disubstituted-6-benzylaminopurine derivatives. In the case of some tumour cell lines, IC(50) values for the complexes (1, 3, 4, 5, 8) are significantly lower than those obtained for cisplatin and oxaliplatin. The best cytotoxicity was achieved for the complex (3) for which IC(50) values range from 1 to 2 microM.


Subject(s)
Kinetin/chemistry , Platinum/chemistry , Antineoplastic Agents/chemical synthesis , Antineoplastic Agents/chemistry , Antineoplastic Agents/toxicity , Benzyl Compounds , Cell Line, Tumor , Humans , In Vitro Techniques , Kinetin/chemical synthesis , Kinetin/toxicity , Magnetic Resonance Spectroscopy , Platinum/toxicity , Purines , Spectrometry, Mass, Electrospray Ionization
4.
Carcinogenesis ; 4(11): 1409-11, 1983 Nov.
Article in English | MEDLINE | ID: mdl-6357521

ABSTRACT

Three plant growth-regulating hormones, indole-3-acetic acid (IAA), indole-3-butyric acid (IBA), and kinetin (6-furfuryl-aminopurine), were tested for their genetic activity in Aspergillus nidulans in a plate test. The first two hormones were found to greatly increase somatic segregation in the fungus whereas kinetin was not effective. Several concentrations of the plant hormones were used and it was found that increasing concentrations of IAA and IBA increased mitotic segregation of the fungus with most of the segregants being produced by mitotic crossing-over, together with non-disjunctional segregants at a lower level. The metabolic activation technique was also used and it was shown that when S9 mixture was added to IAA and IBA a further 3- to 5-fold increase in the number of segregants was obtained. In the case of kinetin the S9 had no effect.


Subject(s)
Aspergillus nidulans/drug effects , Mutagens , Mutation , Plant Growth Regulators/toxicity , Aspergillus nidulans/genetics , Indoleacetic Acids/toxicity , Indoles/toxicity , Kinetin/toxicity , Mutagenicity Tests
SELECTION OF CITATIONS
SEARCH DETAIL
...